公开(公告)号：US08142806B2

公开(公告)日：2012-03-27

申请号：US12401175

申请日：2009-03-10

Applicant: Ramesh C. Gupta ,  Manicka V. Vadhanam

Inventor： Ramesh C. Gupta ,  Manicka V. Vadhanam

IPC: A61F6/18

CPC classification number: A61M31/00 ,  A61K9/0024 ,  A61K9/0036 ,  A61K9/204 ,  A61K9/205 ,  A61K31/01 ,  A61K31/05 ,  A61K31/121 ,  A61K31/366 ,  A61K31/404 ,  A61K31/497

Abstract: The presently-disclosed subject matter provides compositions and methods for treating a cancer by providing a composition comprising a biocompatible polymeric matrix incorporating an effective amount of a phytochemical agent, a combination of phytochemical agents, or a phytochemical agent and a chemotherapeutic agent. Further, provided is a device for uterine cervical insertion for local delivery.

Abstract translation: 目前公开的主题提供了通过提供包含有效量的植物化学试剂，植物化学试剂或植物化学试剂和化学治疗剂的组合的生物相容性聚合物基质的组合物来治疗癌症的组合物和方法。 此外，提供了用于子宫颈插入用于局部递送的装置。

公开(公告)号：US07781451B2

公开(公告)日：2010-08-24

申请号：US11547227

申请日：2005-04-01

Applicant: Gregory R Bebernitz ,  Ramesh C Gupta ,  Vikrant V Jagtap ,  Appaji B Mandhare ,  Davinder Tuli

Inventor： Gregory R Bebernitz ,  Ramesh C Gupta ,  Vikrant V Jagtap ,  Appaji B Mandhare ,  Davinder Tuli

IPC: A61K31/429 ,  C07D513/04

CPC classification number: C07D513/04

Abstract: The present invention provides compounds of the formula which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, Type 2 diabetes and obesity.

Abstract translation: 本发明提供了作为葡萄糖激酶活性的激活剂的下式的化合物，因此可用作治疗葡糖激酶介导的病症的治疗剂。 因此，式（I）化合物可用于预防和治疗葡萄糖耐量异常，2型糖尿病和肥胖症。

公开(公告)号：US20120046267A1

公开(公告)日：2012-02-23

申请号：US13025281

申请日：2011-02-11

Applicant: Keith R. Hornberger ,  Dan M. Berger ,  Xin Chen ,  Andrew P. Crew ,  Hanqing Dong ,  Andrew Kleinberg ,  An-Hu Li ,  Lifu Ma ,  Mark J. Mulvihill ,  Bijoy Panicker ,  Kam W. Siu ,  Arno G. Steinig ,  James G. Tarrant ,  Jing Wang ,  Qinghua Weng ,  Rajaram Sangem ,  Ramesh C. Gupta

Inventor： Keith R. Hornberger ,  Dan M. Berger ,  Xin Chen ,  Andrew P. Crew ,  Hanqing Dong ,  Andrew Kleinberg ,  An-Hu Li ,  Lifu Ma ,  Mark J. Mulvihill ,  Bijoy Panicker ,  Kam W. Siu ,  Arno G. Steinig ,  James G. Tarrant ,  Jing Wang ,  Qinghua Weng ,  Rajaram Sangem ,  Ramesh C. Gupta

IPC: A61K31/4355 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/4709 ,  A61K31/5377 ,  C07D495/04 ,  A61K31/4365 ,  A61K31/519 ,  A61K31/5025 ,  C07D513/04 ,  A61K31/437 ,  C07D487/04 ,  A61K31/4985 ,  A61K31/502 ,  C12N9/99 ,  A61P35/00 ,  A61P29/00 ,  C07D491/048

CPC classification number: C07D491/048

Abstract: Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.

Abstract translation: 式1的化合物，如下文所定义：其药学上可接受的盐，合成，中间体，制剂及其治疗方法，包括治疗癌症，例如至少部分由TAK1驱动的肿瘤，或适合于 TAK1抑制剂有效。 本发明并不限于本发明。